Literature DB >> 11207642

Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy.

A Cagnacci1, S Arangino, M Angiolucci, G B Melis, F Facchinetti, S Malmusi, A Volpe.   

Abstract

OBJECTIVE: Several effects of melatonin are modulated by gonadal steroids and are reduced in ageing women. Administration of melatonin reduces internal carotid artery pulsatility index (PI), and blood pressure in young individuals. Whether these effects are conserved in postmenopausal women and are influenced by hormone replacement therapy (HRT), was herein investigated.
DESIGN: Randomised, double-blind placebo controlled study. PATIENTS: Twenty-three postmenopausal women of which 11 were unreplaced with HRT and 12 on the oestrogenic phase of continuous transdermal estradiol (50 microg/day) plus cyclic medroxyprogesterone acetate (5 mg/day x 12 days every 28 days). MEASUREMENTS: Internal carotid PI, by colour Doppler, and supine blood pressure were evaluated 90, 180 and 240 minutes following the oral administration of melatonin (1 mg) or placebo. Levels of nitrites/nitrates (NOx), the stable derivatives of nitric oxide, were also evaluated in samples collected 90 minutes following the administration of placebo or melatonin.
RESULTS: In women not on replacement therapy melatonin was ineffective. In HRT-treated women, melatonin reduced internal carotid artery PI (P = 0.005). The effect was maximal within 90 minutes, and maintained for at least 240 minutes, with melatonin levels in the nocturnal physiological range. Systolic and diastolic blood pressures were reduced of 8 mmHg (P = 0.038) and 4 mmHg (P = 0.045), respectively, while NOx levels were significantly increased (P = 0.024).
CONCLUSIONS: The circulatory response to melatonin is conserved in postmenopausal women with but not without hormone replacement therapy. Maintenance of the cardiovascular response to melatonin, may be implicated in the reduced cardiovascular risk of postmenopausal women with hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207642     DOI: 10.1046/j.1365-2265.2001.01204.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Actigraphy-derived rest--activity rhythms are associated with nocturnal blood pressure in young women.

Authors:  Elissa K Hoopes; Freda Patterson; Felicia R Berube; Michele N D'Agata; Benjamin Brewer; Susan K Malone; William B Farquhar; Melissa A Witman
Journal:  J Hypertens       Date:  2021-12-01       Impact factor: 4.844

Review 2.  Melatonin for cognitive impairment.

Authors:  S L Jansen; D A Forbes; V Duncan; D G Morgan
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

3.  Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial.

Authors:  Abhinav Goyal; Paul D Terry; Hillary M Superak; Christine L Nell-Dybdahl; Ritam Chowdhury; Lawrence S Phillips; Michael H Kutner
Journal:  Diabetol Metab Syndr       Date:  2014-11-18       Impact factor: 3.320

4.  Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer.

Authors:  Balasunder R Dodda; Corry D Bondi; Mahmud Hasan; William P Clafshenkel; Katie M Gallagher; Mary P Kotlarczyk; Shalini Sethi; Ethan Buszko; Jean J Latimer; J Mark Cline; Paula A Witt-Enderby; Vicki L Davis
Journal:  Front Oncol       Date:  2019-07-09       Impact factor: 6.244

Review 5.  Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases.

Authors:  Virna Margarita Martín Giménez; Natalia de Las Heras; Vicente Lahera; Jesús A F Tresguerres; Russel J Reiter; Walter Manucha
Journal:  Front Aging Neurosci       Date:  2022-06-03       Impact factor: 5.702

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.